BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33990091)

  • 1. Endometrial Carcinoma as the Presenting Malignancy in a Teenager With a Pathogenic TP53 Germline Mutation: A Case Report and Literature Review.
    Irshaid L; Clark M; Fadare O; Finberg KE; Parkash V
    Int J Gynecol Pathol; 2022 May; 41(3):258-267. PubMed ID: 33990091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
    Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
    Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nodular Lymphocyte-predominant Hodgkin Lymphoma in a 15-Year-Old Boy With Li-Fraumeni Syndrome Having a Germline TP53 D49H Mutation.
    Yamazaki F; Shima H; Osumi T; Narumi S; Kuroda T; Shimada H
    J Pediatr Hematol Oncol; 2018 Apr; 40(3):e195-e197. PubMed ID: 28902083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High frequency of de novo mutations in Li-Fraumeni syndrome.
    Gonzalez KD; Buzin CH; Noltner KA; Gu D; Li W; Malkin D; Sommer SS
    J Med Genet; 2009 Oct; 46(10):689-93. PubMed ID: 19556618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First case of endometrial cancer after yolk sac tumor in a patient with Li-Fraumeni syndrome.
    Ye QL; Qi Y; Liu JJ; Hu YX; Lv Y; Lin B
    BMC Womens Health; 2023 Jun; 23(1):329. PubMed ID: 37344881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
    Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
    Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
    Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
    JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
    Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
    J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rectal leiomyosarcoma as the initial phenotypic manifestation of Li-Fraumeni-like syndrome: a case report and review of the literature.
    Severino NP; Waisberg J; Fragoso MCBV; de Lima LGCA; Balsamo F; Henriques AC; Bianco B; de Sousa Gehrke F
    J Med Case Rep; 2022 Dec; 16(1):468. PubMed ID: 36529791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
    Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
    Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage.
    Zerdoumi Y; Lanos R; Raad S; Flaman JM; Bougeard G; Frebourg T; Tournier I
    Hum Mol Genet; 2017 Jul; 26(14):2591-2602. PubMed ID: 28369373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
    Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
    Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of germline p53 mutations in childhood adrenocortical cancer.
    Wagner J; Portwine C; Rabin K; Leclerc JM; Narod SA; Malkin D
    J Natl Cancer Inst; 1994 Nov; 86(22):1707-10. PubMed ID: 7966399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A first report of a rare TP53 variant associated with Li-Fraumeni syndrome manifesting as invasive breast cancer and malignant solitary fibrous tumor.
    Prejac J; Dedić Plavetić N; Gotovac Jerčić K; Borovečki F
    World J Surg Oncol; 2021 Aug; 19(1):254. PubMed ID: 34452612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing.
    Zampiga V; Danesi R; Tedaldi G; Tebaldi M; Cangini I; Pirini F; Pittureri C; Amaducci E; Guidi L; Faedi M; Amadori D; Falcini F; Calistri D
    Int J Biol Markers; 2016 Dec; 31(4):e461-e465. PubMed ID: 27516001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
    Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
    JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
    Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
    BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome.
    Amadou A; Achatz MIW; Hainaut P
    Curr Opin Oncol; 2018 Jan; 30(1):23-29. PubMed ID: 29076966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.